Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

________________________

Washington, D.C. 20549

_____________________

FORM 6-K

_____________________

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of November 2024

Commission File Number: 001-37835

________________________________________

Indivior PLC

________________________________________

10710 Midlothian Turnpike, Suite 125

North Chesterfield, Virginia 23235

(Address of principal executive office)

_______________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit No.	Description of Exhibit
99.1	Announcement sent to the London Stock Exchange on November 15, 2024, titled “Director Declaration”.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Indivior PLC
Date: November 15, 2024	/s/ Kathryn Hudson
	Name: Kathryn Hudson
	Title: Company Secretary

Exhibit 99.1

INDIVIOR PLC (the 'Company')

DIRECTOR DECLARATION

Richmond, VA, and Slough, UK, November 15, 2024 - The Board of Directors of Indivior PLC (Nasdaq/LSE: INDV) have agreed that Jerome Lande will continue to serve as a Non-Executive Director until December 31, 2024, whereupon he will step down from the Board.

The Company's relationship agreement with Scopia Capital Management LP ("Scopia"), otherwise due to expire on December 31, 2024, has terminated in accordance with its terms because the aggregate of Scopia's and its affiliates' interests in the issued share capital of the Company has reduced below the threshold for automatic termination. Notwithstanding that the threshold for automatic termination has been crossed, the Board and Scopia have agreed that Jerome Lande will continue to serve as a Non-Executive Director until December 31, 2024.

The Board would like to express its sincere thanks to Jerome for his significant contribution to Indivior since joining the Board in 2021.

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

For Further Information

Investor Enquiries	Jason Thompson	VP, Investor Relations Indivior PLC	+1 804 402 7123 jason.thompson@indivior.com
	Tim Owens	Director, Investor Relations Indivior PLC	+1 804 263 3978 timothy.owens@indivior.com
Media Enquiries	Jonathan Sibun	Teneo U.S. Media Inquiries	+44 (0)20 7353 4200 +1 804 594 0836 Indiviormediacontacts@indivior.com